1-8 of 8
Takahiko Seki
Close
Sort by
Journal Articles

Single-Cell Proteomic Interrogation of FLT3-ITD Leukemia Compartment Revealsdistinct Leukemia Cell Populations Resistant to Quizartinib, Decitabine and Venetoclax

Muharrem Muftuoglu, Musa Yilmaz, Mahesh Basyal, Li Li, Takahiko Seki, Arnaud Lesegretain, Naval Daver, Michael Andreeff
Journal: Blood
Blood (2022) 140 (Supplement 1): 2273–2274.
https://doi.org/10.1182/blood-2022-171124
Published: 2022
Journal Articles

Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML

Yuki Nishida, Jo Ishizawa, Edward Ayoub, Tallie Patsilevas, Lauren Ostermann, Rafael Heinz Montoya, Muharrem Muftuoglu, Vivian Ruvolo, Po Yee Mak, Wenjing Tao, Bing Z Carter, Kensuke Kojima, Naval Daver, Arnaud Lesegretain, Takahiko Seki, Sharon Shacham, Marina Konopleva, Michael Andreeff
Journal: Blood
Blood (2021) 138 (Supplement 1): 505.
https://doi.org/10.1182/blood-2021-149260
Published: 2021
Journal Articles

Synergistic Anti-Leukemic Activity with Combination of FLT3 Inhibitor Quizartinib and MDM2 Inhibitor Milademetan in FLT3-ITD Mutant/p53 Wild-Type Acute Myeloid Leukemia Models

Michael Andreeff, MD PhD, Weiguo Zhang, MD PhD, Prasanna Kumar, PhD, Oleg Zernovak, MD, Naval G. Daver, MD, Takeshi Isoyama, PhD, Kouichi Iwanaga, D.V.M, PhD, Noriko Togashi, Takahiko Seki, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2720.
https://doi.org/10.1182/blood-2018-99-115183
Published: 2018
Journal Articles

Activation of p53 Enhances Antileukemia Activity of Bcr-Abl Tyrosine Kinase Inhibitors in a Murine Model of CML

Bing Z Carter, PhD, Po Yee Mak, Hong Mu, MD PhD, Duncan Mak, Ej Dettman, Michael Cardone, Xiangmeng Wang, PhD, Wendy Schober, Wenjing Tao, PhD, Takahiko Seki, Michael Andreeff, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4170.
https://doi.org/10.1182/blood.V130.Suppl_1.4170.4170
Published: 2017
Journal Articles

Discovery of Predictive Gene Signatures for Tumor Sensitivity to MDM2 Inhibition in Development of a Novel MDM2 Inhibitor DS-3032b

Jo Ishizawa, MD PhD, Kenji Nakamaru, Takahiko Seki, Koichi Tazaki, Kensuke Kojima, MD PhD, Dhruv Chachad, Courtney D DiNardo, MD, Sherry Pierce, BSN, BA, Keyur P. Patel, MD PhD, Archie Tse, R Eric Davis, MD, Arvind Rao, PhD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2893.
https://doi.org/10.1182/blood.V128.22.2893.2893
Published: 2016
Journal Articles

The Role of IDH Mutants, Which Are Promising Therapeutic Targets for Acute Myeloid Leukemia

Yoko Ogawara, PhD, Hironori Matsunaga, Takahiko Seki, PhD, Yukino Machida, Kazushi Araki, D.V.M., PhD, Issay Kitabayashi, PhD
Journal: Blood
Blood (2015) 126 (23): 3796.
https://doi.org/10.1182/blood.V126.23.3796.3796
Published: 2015
Journal Articles

The Novel Human Double Minute (HDM)-2 Inhibitor DS-5272 Is Active Both Alone, and In Combination With Other Novel Agents, Against Multiple Myeloma

Dongmin Gu, M.D., Ph.D., Hua Wang, Ph.D., Zhiqiang Wang, Ph.D., Richard E. Davis, M.D., Shengli Cai, M.D., Ph.D., Takahiko Seki, Ph.D., Archie Tse, M.D., Ph.D., Robert Z. Orlowski, M.D., Ph.D
Journal: Blood
Blood (2013) 122 (21): 1927.
https://doi.org/10.1182/blood.V122.21.1927.1927
Published: 2013
Journal Articles

Critical Roles Of The IDH2 Mutation In Development and Maintenance Of Acute Myeloid Leukemia

Yoko Ogawara, PhD, Takuo Katsumoto, PhD, Yukiko Aikawa, Yutaka Shima, PhD, Yuki Kagiyama, PhD, Hironori Matsunaga, Takahiko Seki, Ph.D., Issay Kitabayashi, PhD
Journal: Blood
Blood (2013) 122 (21): 225.
https://doi.org/10.1182/blood.V122.21.225.225
Published: 2013